Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01853345 · ClinicalTrials.gov registry record
iCAT for Recurrent/Refractory/HR Solid Tumors
A clinical trial of Sarcoma and Neuroblastoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 101
- Enrollment target
- 5
- Study locations
NCT01853345: Completed study of Sarcoma and Neuroblastoma, sponsored by Dana-Farber Cancer Institute.
NCT01853345 is a study of Sarcoma and Neuroblastoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 101 participants, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (89% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01853345, a study of Sarcoma and Neuroblastoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 101 participants
- Enrollment target
- 5
- Study locations
Study Summary
In this study tumor will be tested for cancer causing gene alterations such as mutations or copy number alterations. This is called tumor profiling. A panel of experts will review the tumor profiling results and determine whether there is a cancer-causing alteration present in the tumor. If there is, the experts will determine if there is a targeted drug available that could counteract this alteration. If there is an alteration identified and a targeted drug available the panel of experts will make an individualized treatment recommendation. The results of the tumor profiling and the individualized treatment recommendation can be shared with the primary oncologist.
Conditions Studied
Study Locations (5)
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Boston Children's Hospital - Boston
California
- University of California, San Francisco - San Francisco
District of Columbia
- Children's National Medical center - Washington D.C.
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2012-08 |
What the finished NCT01853345 record still lists
NCT01853345 is an observational study that tracks outcomes without assigning an intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (89% lower).
The record links to 4 conditions, with Sarcoma appearing as the primary indexed condition, and to 0 interventions.
NCT01853345 lists 5 locations in 4 states (Massachusetts, California, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT01853345 about?
NCT01853345 is a clinical study titled "iCAT for Recurrent/Refractory/HR Solid Tumors". In this study tumor will be tested for cancer causing gene alterations such as mutations or copy number alterations. This is called tumor profiling. A panel of experts will review the tumor profiling results and determine whether there is a cancer-causing alteration present in the tumor. If there is...
What is the current status of trial NCT01853345?
This trial is currently completed. The enrollment target is 101 participants. The study started on 2012-08.
What conditions does trial NCT01853345 study?
This clinical trial studies the following conditions: Sarcoma, Neuroblastoma, Wilms Tumor, Pediatric Solid Tumor.
Who is sponsoring clinical trial NCT01853345?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01853345 being conducted?
This trial has 5 study locations across California, District of Columbia, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01853345's enrollment target sits among peer trials
101 41st of 122 higher than 82 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
RECRUITING
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
RECRUITING
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Enhanced Recovery After Surgery in Extremity Sarcoma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia